Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China

Kehui Meng; Heng Xiang; Meiyu Wu; Ouyang Xie; Andong Li; Chongqing Tan; Xiaomin Wan

doi:10.3389/fphar.2024.1382342

Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China

Front Pharmacol. 2024 Nov 5:15:1382342. doi: 10.3389/fphar.2024.1382342. eCollection 2024.

Authors

Kehui Meng¹, Heng Xiang¹, Meiyu Wu¹, Ouyang Xie¹, Andong Li¹, Chongqing Tan¹, Xiaomin Wan¹

Affiliation

¹ Department of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China.

Abstract

Aims: Assessing the cost-effectiveness of Nivolumab with Gemcitabine-Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.

Methods: A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.

Results: The base-case analysis showed Nivolumab plus Gemcitabine-Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab's cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine-Cisplatin in aUC treatment.

Conclusion: Nivolumab plus Gemcitabine-Cisplatin is not cost-effective in the treatment of aUC.

Keywords: Pharmacoeconomics; advanced urothelial carcinoma; cost-effectiveness; immunotherapy; nivolumab; quality adjusted life years.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Funding provided by The National Natural Science Foundation of China (grant numbers: 82073818).